



23 November 2004

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

TGA to list FerriScan™ for Australia with reciprocal access to CE Mark for European markets

Perth, Australia, Tuesday 23 November 2004: Resonance Health Limited (ASX:RHT) is pleased to announce that its FerriScan™ test for non-invasive measurement of liver iron concentration is to be listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA). Registration in European markets can follow as a result of reciprocal arrangements between the TGA and its European counterparts. The Australian listing has arisen from the submission previously announced by Resonance Health subsidiary, Inner Vision Biometrics Pty Ltd (IVB) in April 2004.

The material prepared for the TGA in Australia will form the basis of a US FDA 510(k) regulatory submission for FerriScan™ for filing within 28 days. As the largest market for the FerriScan™, the US has a well developed MRI infrastructure and attractive pricing. The Pre-market notification or 510(k) allows the FDA to determine whether a device is equivalent to one that has already been classified. It is a much faster process than FDA approval for drugs and once approved the device is able to be sold to the US market.

The Managing Director of Resonance Health, Mr Tony Fitzgerald, said: "Australian listing by the TGA and reciprocal listing with European authorities will give FerriScan™ access to Australian and major European markets. After the launch, FerriScan™ will initially be available to a select group of Australian magnetic resonance imaging (MRI) centres, followed by a national roll out to privately-owned and public MRI centres in 2005. The launch in Europe will follow, commencing in the United Kingdom."

The Chairman of Resonance Health, Dr Michael Wooldridge, said: "The commercial launch of FerriScan™ heralds a new era of non-invasive testing worldwide for patients with iron overload. I commend the high quality Australian science behind FerriScan™ which I believe provides an excellent opportunity to build a commercially-successful global testing service."

FerriScan™ is a novel, non-invasive technology for liver diagnosis, designed as an alternative to needle biopsies of the liver for the measurement of iron concentration. The technology has the potential for broader application in other liver diseases, such as fibrosis caused by hepatitis.

About Resonance Health Ltd:

Resonance Health Limited controls 51% of the voting rights of Inner Vision Biometrics Pty Ltd (IVB) and is earning 51% of the equity of IVB via the progressive injection of further capital. FerriScan™ is 100% owned by IVB

FerriScan™ is a novel, non-invasive liver diagnostic test. The test measures the iron content of a patient's liver to assist clinicians in the detection and treatment of iron overload disorders such as thalassemia and hereditary haemochromatosis. It is intended that the FerriScan™ test will replace the need for liver biopsy and become a valuable adjunct to gene testing for iron overload diseases. Liver biopsy is an unpleasant, invasive procedure requiring liver tissue to be extracted from the patient by needle.

IVB aims to be a global leader in the development and commercialisations of quantitative magnetic resonance imaging techniques for the diagnosis and clinical management of disease through:

- Establishing FerriScan™ as the 'gold standard' for liver iron assessment across the world.
- Expanding the potential applications of the technology platform into areas where it addresses unmet clinical needs (e.g. liver fibrosis, fatty liver disease).

The technology platform is expected to be used next for the development of a non-invasive test for liver cirrhosis and fibrosis for monitoring patients with progressive liver diseases, including hepatitis C.

Further information concerning Resonance Health and FerriScan™ can be obtained from the following web sites: www.resonancehealth.com www.ferriscan.com

Media and Investor Relations	Company
Rebecca Christie Buchan Consulting Pty Ltd SYDNEY: T - +61 2 9293 2836 F - +61 2 9293 2828 M - 0417 382 391 Rchristie@bcg.com.au	Tony Fitzgerald Director, Resonance Health Ltd T - +61 8 9389 5933 M - 0418 903 647; or Dr James Williams CEO, Inner Vision Biometrics Pty Ltd T - +61 9286 5300 M 0409 050 519 Email: jamesw@ferriscan.com